List of Excipients in Branded Drug VECAMYL

« Back to Dashboard

Generic Drugs Containing VECAMYL

Company	Ingredient	NDC	Excipient
Manchester Pharmaceuticals	mecamylamine hydrochloride	45043-558	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
Manchester Pharmaceuticals	mecamylamine hydrochloride	45043-558	D&C YELLOW NO. 10
Manchester Pharmaceuticals	mecamylamine hydrochloride	45043-558	FD&C YELLOW NO. 6
Manchester Pharmaceuticals	mecamylamine hydrochloride	45043-558	LACTOSE MONOHYDRATE
Manchester Pharmaceuticals	mecamylamine hydrochloride	45043-558	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in VECAMYL?

# Of NDCs	Excipient
3	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
3	D&C YELLOW NO. 10
3	FD&C YELLOW NO. 6
3	LACTOSE MONOHYDRATE
3	MAGNESIUM STEARATE

VECAMYL Excipient Strategy and Commercial Opportunities for Mecamylamine Hydrochloride

Last updated: September 24, 2026

VECAMYL is an oral mecamylamine hydrochloride tablet approved historically for hypertension. Its commercial opportunity is limited in the conventional antihypertensive market because ganglionic blockers have largely been replaced by safer, better-tolerated therapies. The stronger opportunities are low-volume specialty products, reformulated oral dosage forms, investigator-sponsored CNS applications, and contract manufacturing of a technically simple but commercially differentiated tablet.

The principal formulation issue is not solubility. Mecamylamine hydrochloride is a potent, low-dose active pharmaceutical ingredient, so content uniformity, dose flexibility, stability, tablet identification and tolerability are more important than high drug loading. A modern generic or lifecycle product should prioritize robust low-dose manufacturing and a clean excipient profile.

What is VECAMYL and what is its FDA regulatory status?

VECAMYL contains mecamylamine hydrochloride, a secondary-amine ganglionic nicotinic receptor antagonist. The historical product was supplied as oral tablets in multiple strengths, including 2.5 mg, 5 mg and 10 mg presentations. Its approved use was the treatment of moderate to severe hypertension, generally when other antihypertensive approaches were inadequate or unsuitable.

Attribute	VECAMYL
Active ingredient	Mecamylamine hydrochloride
Drug class	Ganglionic nicotinic receptor antagonist
Dosage form	Immediate-release oral tablet
Historical strengths	2.5 mg, 5 mg and 10 mg
Main approved use	Hypertension
FDA pathway for an equivalent product	Likely ANDA, subject to reference-product and listing status
Reformulation pathway	Potentially 505(b)(2), depending on the proposed change
Primary formulation risk	Low-dose content uniformity
Primary clinical risk	Orthostatic hypotension and anticholinergic-like adverse effects

FDA labeling describes mecamylamine as a potent antihypertensive with dose-related adverse effects, including constipation, urinary retention, blurred vision, dry mouth and orthostatic hypotension. These characteristics constrain commercial repositioning and favor tightly controlled dosing over high-dose or modified-release concepts. [1]

What excipients are used in VECAMYL tablets?

Public labeling historically identifies conventional tablet excipients, including lactose, corn starch, talc and magnesium stearate. Exact supplier grades, quantities, particle-size distributions and manufacturing process parameters are not generally disclosed in a commercial label.

Excipient category	Likely role in VECAMYL-type tablets	Strategic assessment
Lactose	Diluent and compression aid	Economical, familiar to regulators, but unsuitable for patients with significant lactose intolerance and subject to moisture and Maillard-reaction assessment
Corn starch	Filler, disintegrant or binder after processing	Supports immediate release; grade selection affects disintegration and tablet strength
Talc	Glidant or anti-adherent	Can improve manufacturability; requires control of grade, particle size and regulatory compliance
Magnesium stearate	Lubricant	Essential for compression performance, but over-lubrication can reduce tablet tensile strength and slow dissolution
Optional colloidal silicon dioxide	Glidant and flow aid	Useful in direct compression if powder flow is inadequate
Optional povidone or pregelatinized starch	Binder	Can improve granule strength and content uniformity in wet or dry granulation

The low dose creates a distribution problem. At a 2.5 mg strength, active ingredient may represent only a small fraction of total tablet mass. Simple blending may produce unacceptable potency variability unless the API has suitable particle-size distribution and the blend has low segregation potential.

How should an excipient strategy address low-dose mecamylamine?

A commercially robust formulation should begin with a target tablet weight that permits accurate dosing without creating an unnecessarily large tablet. Increasing the proportion of diluent improves content uniformity, but excessive tablet mass can reduce patient acceptability and raise manufacturing costs.

Direct-compression strategy

Direct compression is the most attractive initial platform when the selected mecamylamine hydrochloride grade has adequate flow and compressibility. A typical architecture would use:

• Lactose or microcrystalline cellulose as the principal diluent
• Crospovidone, croscarmellose sodium or starch as the disintegrant
• Colloidal silicon dioxide as a flow aid where required
• Magnesium stearate at the lowest level that supports ejection
• A colorant or distinctive imprint for strength differentiation

Direct compression reduces processing steps and eliminates granulation-related exposure to water or heat. It also makes segregation control more important. The active should be screened for particle-size distribution, bulk density, electrostatic behavior and tendency to adhere to equipment.

Dry-granulation strategy

Roller compaction or slugging may be preferable if the API-diluent blend has poor flow or if content uniformity is unstable during high-speed tableting. Dry granulation avoids water exposure and can improve bulk density. It may, however, create dense granules that delay disintegration if the formulation is overcompacted.

Wet-granulation strategy

Wet granulation is less attractive as a default option because it adds process complexity and requires confirmation of aqueous and thermal stability. It may be justified where the low-dose blend cannot meet uniformity or flow specifications through direct compression and dry granulation.

Which excipients are most commercially attractive for a modern VECAMYL equivalent?

The best commercial strategy is a conservative, compendial excipient system with a documented rationale for each component.

Lactose-based formulation

A lactose-based formula most closely reflects the historical product concept and supports low-cost manufacturing. It is suitable for a conventional generic tablet if stability and dissolution are acceptable.

Commercial advantages include:

• Low excipient cost
• Broad supplier availability
• Familiar regulatory history
• Good tablet-size economics
• Compatibility with direct compression or granulation

The principal limitation is the presence of lactose. A lactose-free version could provide a modest differentiation point, but the clinical value may be limited because lactose content in a small tablet is unlikely to be material for most patients.

Microcrystalline-cellulose formulation

Microcrystalline cellulose can improve compactability and reduce dependence on lactose. It is useful where the product must be lactose-free or where tablet mechanical strength is inadequate.

The tradeoff is a potentially higher tablet weight and different dissolution behavior. Grade selection can materially affect flow, tensile strength and disintegration.

Co-processed excipients

Co-processed excipients may simplify development by combining a diluent with a disintegrant or flow aid. They can improve manufacturing robustness for low-dose APIs, but they also increase reliance on a specific supplier and may complicate postapproval sourcing changes.

Taste-masked or orally disintegrating formulation

Mecamylamine is a potent, water-soluble compound. An orally disintegrating tablet could improve administration for selected patients, but taste masking would be necessary if the tablet disintegrates in the mouth. Ion-exchange resins, polymeric coatings or multiparticulate technologies could be evaluated.

The commercial case is uncertain. VECAMYL is not primarily limited by swallowing difficulty, and an orally disintegrating product could increase development, packaging and stability costs without expanding the treated population sufficiently.

What formulations are protected or commercially differentiated?

The historical immediate-release tablet is unlikely to support meaningful exclusivity based on the active ingredient alone. Mecamylamine hydrochloride has been known and used clinically for decades. The more realistic differentiation opportunities are formulation and product-design claims, including:

1. A low-dose tablet with improved content uniformity.
2. A lactose-free or excipient-reduced tablet.
3. An orally disintegrating or taste-masked dosage form.
4. A scored tablet with improved dose flexibility.
5. A modified-release formulation intended to reduce peak-related hypotension.
6. A combination product with another antihypertensive.
7. A formulation targeting investigational CNS indications.

Any patent value would depend on unexpected clinical or pharmaceutical benefits, not merely substitution of one conventional filler for another. A formulation patent would need credible comparative data showing improved stability, dissolution, tolerability, adherence or pharmacokinetic control.

When does VECAMYL lose exclusivity?

The original composition and product exclusivity for VECAMYL are long expired or otherwise commercially exhausted. Mecamylamine hydrochloride was approved in the mid-20th century, placing the original active-ingredient patent estate outside the normal term of current U.S. pharmaceutical patents.

The relevant commercial question is therefore not loss of original exclusivity. It is whether a current reference product, FDA-approved labeling, or later formulation patent creates a practical barrier to an equivalent product.

Exclusivity element	Commercial assessment
Original compound patent	Expired by ordinary patent-term timelines
Original product patent	Expected to be expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	No material current barrier identified
Orphan exclusivity	Not associated with the historical hypertension product
Formulation exclusivity	Must be assessed against any later approved product or patent filing
Reference-product dependence	Critical for an ANDA strategy

An ANDA applicant would need to confirm the currently designated reference listed drug, active Orange Book patents and applicable exclusivity codes before filing. Historical approval alone does not establish that a current reference product remains available for a conventional ANDA.

What is the Orange Book status of VECAMYL?

The Orange Book analysis should distinguish among three issues:

• Whether VECAMYL or another mecamylamine hydrochloride product is currently listed as a reference drug.
• Whether the product has been withdrawn for safety or only for commercial reasons.
• Whether any patents or exclusivity periods are currently listed.

If the drug is listed as discontinued for commercial reasons and FDA has not determined that the withdrawal was for safety or effectiveness concerns, an applicant may still evaluate a suitability petition or another regulatory route. A 505(b)(2) application may be more practical for a new dosage form, new strength or new clinical use.

A Paragraph IV challenge is relevant only if an unexpired patent is listed against the reference product. Given the age of VECAMYL, the more likely barriers are reference-product availability, bioequivalence design and limited market demand rather than a mature blocking patent estate.

What generic entry risks exist for VECAMYL?

Generic entry would face modest intellectual-property risk but substantial commercial and regulatory execution risk.

Regulatory risks

The main regulatory issues are:

• Demonstrating bioequivalence at a low dose
• Meeting content-uniformity requirements across all strengths
• Establishing dissolution discrimination
• Managing dose proportionality between 2.5 mg, 5 mg and 10 mg tablets
• Confirming the appropriate reference listed drug
• Addressing discontinued or limited-market reference-product status

A waiver for lower strengths may be possible only if the formulation is proportionally similar and the pharmacokinetic and dissolution data support the request.

Manufacturing risks

Low-dose products are vulnerable to:

• Blend segregation
• API adherence to blender and tablet-press surfaces
• Lubricant overuse
• Potency variability during hopper discharge
• Cross-contamination in multiproduct facilities
• Inconsistent tablet hardness and disintegration

A quality-by-design program should establish a design space around API particle size, blend time, lubricant concentration, compression force and tablet weight.

Commercial risks

The hypertension market is dominated by inexpensive generic agents such as thiazide diuretics, ACE inhibitors, angiotensin-receptor blockers and calcium-channel blockers. VECAMYL would not compete effectively on broad primary-care demand.

A viable product would require one or more of the following:

• A reliable supply position in a niche market
• Premium pricing based on scarcity or availability
• A specialty distributor strategy
• Institutional demand
• A lifecycle formulation with a measurable adherence or tolerability advantage
• Clinical development in a non-hypertension indication

Which companies are likely to compete with a VECAMYL product?

Competition is more likely to come from therapeutic substitutes than from direct mecamylamine products. In hypertension, physicians can select from multiple low-cost generic classes with substantially broader use and better-established safety profiles.

Direct competitive categories include:

Category	Competitive effect
Generic antihypertensives	Reduces demand for mecamylamine in routine hypertension
Compounded mecamylamine	May compete in supply-constrained or individualized use cases
Specialty pharmacies	Could support limited-volume distribution
Investigational CNS products	Could create a higher-value market if clinical efficacy is established
Other ganglionic blockers	Limited practical competition because the class is obsolete

Biosimilar risk is not relevant. Mecamylamine is a small molecule, not a biologic, and would be regulated through generic or 505(b)(2) pathways rather than biosimilar approval.

What licensing and partnership opportunities exist?

The most credible licensing model would involve a specialty pharmaceutical company acquiring or licensing:

• A reformulated mecamylamine tablet
• A low-dose manufacturing platform
• Rights to a new indication
• A combination product
• A regional commercialization package

The commercial value of a license would depend on clinical differentiation. A conventional tablet with no supply advantage would have limited licensing appeal. A product supported by clinical data in smoking cessation, neuropsychiatry or another defined population could attract a higher-value partner, but the development risk would be materially greater.

The historical use of mecamylamine in CNS research does not establish an approved indication. Any commercial claim outside hypertension would require appropriate clinical evidence and FDA review.

How strong is the VECAMYL patent estate?

The original patent estate is weak from a current exclusivity perspective because the active ingredient and historical product are old. The strongest potential protection would come from later patents covering:

• A specific controlled-release profile
• A novel salt, polymorph or particle-size distribution
• A clinically differentiated combination
• A new therapeutic indication
• A formulation with demonstrated stability or tolerability advantages

Routine excipient substitution is unlikely to create durable patent protection. The practical freedom-to-operate position should focus on later formulation, method-of-use and combination patents rather than the expired original compound rights.

What is the commercial outlook for VECAMYL?

Opportunity	Attractiveness	Reason
Conventional generic hypertension tablet	Low	Crowded market and limited clinical use
Supply-reliable niche tablet	Moderate	Could address availability problems
Lactose-free formulation	Low to moderate	Easy differentiation, limited clinical premium
Orally disintegrating tablet	Moderate	Potential adherence benefit, but taste and stability challenges
Modified-release product	Moderate to high	Could address peak-related tolerability, but requires clinical development
Smoking-cessation product	Moderate to high	Historical mechanistic rationale, significant efficacy and safety risk
CNS adjunctive therapy	High upside, high risk	Requires new clinical evidence and regulatory approval
Combination antihypertensive	Moderate	May improve positioning but faces strong generic competition

Key Takeaways

• VECAMYL is an old mecamylamine hydrochloride tablet with limited relevance to mainstream hypertension treatment.
• The core excipient challenge is low-dose content uniformity, not dissolution or drug loading.
• Lactose, starch, talc and magnesium stearate support a conventional low-cost formulation, but modern development may favor microcrystalline cellulose and a stronger disintegrant system.
• Direct compression is attractive if powder flow and blend uniformity can be controlled.
• A lactose-free, orally disintegrating or modified-release product could create differentiation, but each requires a clear clinical or commercial benefit.
• Original compound and product exclusivity are no longer meaningful barriers.
• Current Orange Book and reference-listed-drug status determine whether an ANDA is practical.
• The largest commercial upside lies outside routine hypertension, particularly in specialty supply, reformulation and clinically supported new indications.
• Biosimilar competition does not apply because mecamylamine is a small molecule.
• A conventional VECAMYL generic is more exposed to limited demand and regulatory execution risk than to patent litigation.

Frequently Asked Questions

Is mecamylamine hydrochloride still FDA approved?

Mecamylamine hydrochloride has historical FDA approval as an antihypertensive. Current marketing and reference-product status must be evaluated separately from the original approval history.

Can VECAMYL be reformulated without new clinical trials?

A compositionally equivalent immediate-release tablet may qualify for an ANDA if an appropriate reference product exists. A new release profile, dosage form, indication or clinical use may require a 505(b)(2) application and additional studies.

Is lactose necessary in a mecamylamine tablet?

No. Lactose is a practical diluent, but microcrystalline cellulose, mannitol and other compendial fillers may support lactose-free formulations if content uniformity, dissolution and stability requirements are met.

Could mecamylamine be developed as a smoking-cessation drug?

Mecamylamine has been investigated for CNS and smoking-related applications, but investigational evidence does not equal FDA approval. A commercial product for smoking cessation would require clinical evidence supporting efficacy, dosing and safety.

Does VECAMYL have biosimilar competition?

No. Mecamylamine hydrochloride is a small molecule. Competitive products would be generics, reformulations or 505(b)(2) products, not biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). VECAMYL (mecamylamine hydrochloride) tablets: Prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. National Library of Medicine. (n.d.). Mecamylamine hydrochloride drug labeling. DailyMed.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.